HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

A David Marais Selected Research

Hyperlipoproteinemia Type III (Broad Beta Disease)

10/2022Establishing the relationship between familial dysbetalipoproteinemia and genetic variants in the APOE gene.
1/2022Genetic and Mechanistic Insights into the Modulation of Circulating Lipoprotein (a) Concentration by Apolipoprotein E Isoforms.
9/2021Hyperlipidemic myeloma, a rare form of acquired dysbetalipoproteinemia, in an HIV seropositive African female.
1/2021Adiposity and the development of dyslipidemia in APOE ε2 homozygous subjects: A longitudinal analysis in two population-based cohorts.
11/2017Effect of adding bezafibrate to standard lipid-lowering therapy on post-fat load lipid levels in patients with familial dysbetalipoproteinemia. A randomized placebo-controlled crossover trial.
4/2017Familial dysbetalipoproteinemia: an underdiagnosed lipid disorder.
1/2017Autosomal dominant familial dysbetalipoproteinemia: A pathophysiological framework and practical approach to diagnosis and therapy.
12/2008Rosuvastatin reduces non-high-density lipoprotein cholesterol and lipoprotein remnants in patients with dysbetalipoproteinemia (Fredrickson type III hyperlipoproteinemia).
5/2005Screening for dysbetalipoproteinemia by plasma cholesterol and apolipoprotein B concentrations.
1/2003Non-denaturing polyacrylamide gradient gel electrophoresis for the diagnosis of dysbetalipoproteinemia.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


A David Marais Research Topics

Disease

14Hyperlipoproteinemia Type II (Familial Hypercholesterolemia)
01/2021 - 07/2003
10Hyperlipoproteinemia Type III (Broad Beta Disease)
10/2022 - 01/2003
9Cardiovascular Diseases (Cardiovascular Disease)
01/2021 - 12/2008
7Atherosclerosis
02/2019 - 04/2008
6Hypercholesterolemia
01/2015 - 07/2003
6Homozygous Familial Hypercholesterolemia
12/2014 - 12/2003
5Hyperlipidemias (Hyperlipidemia)
09/2021 - 01/2003
5Inborn Genetic Diseases (Disease, Hereditary)
11/2017 - 12/2008
4Dyslipidemias (Dyslipidemia)
10/2022 - 08/2007
4Coronary Artery Disease (Coronary Atherosclerosis)
01/2017 - 12/2005
3Heart Diseases (Heart Disease)
08/2012 - 02/2004
2Insulin Resistance
04/2017 - 01/2017
2Infections
03/2014 - 01/2013
1Multiple Myeloma
09/2021
1HIV Infections (HIV Infection)
09/2021
1Genetic Predisposition to Disease (Genetic Predisposition)
01/2021
1Human Influenza (Influenza)
11/2019
1Hyperlipoproteinemia Type I (Lipoprotein Lipase Deficiency, Familial)
04/2019
1Pancreatitis
04/2019
1Alzheimer Disease (Alzheimer's Disease)
02/2019
1Lipoprotein Glomerulopathy
02/2019
1Cardiomyopathies (Cardiomyopathy)
01/2018
1Obesity
04/2017
1Xanthomatosis (Xanthoma)
04/2017
1Metabolic Diseases (Metabolic Disease)
08/2013
1Bacterial Infections (Bacterial Infection)
01/2013
1Listeriosis (Listeria Infection)
01/2013
1Carotid Artery Diseases
07/2010
1Injection Site Reaction
03/2010
1Proteinuria
08/2007
1Obstructive Jaundice (Cholestatic Jaundice)
04/2006
1Liver Diseases (Liver Disease)
04/2006

Drug/Important Bio-Agent (IBA)

12LipidsIBA
01/2022 - 12/2003
11Lipoproteins (Lipoprotein)IBA
10/2022 - 01/2003
10CholesterolIBA
10/2022 - 01/2003
9LDL CholesterolIBA
01/2021 - 02/2008
9LDL Receptors (LDL Receptor)IBA
04/2017 - 12/2005
8oxidized low density lipoproteinIBA
10/2018 - 01/2003
7ApolipoproteinsIBA
02/2019 - 01/2003
6Triglycerides (Triacylglycerol)IBA
01/2022 - 01/2003
5Hydroxymethylglutaryl-CoA Reductase Inhibitors (HMG-CoA Reductase Inhibitors)IBA
04/2017 - 07/2010
4Apolipoproteins E (ApoE)IBA
10/2022 - 01/2017
4Proprotein Convertase 9IBA
01/2021 - 08/2007
4LDL Lipoproteins (beta Lipoproteins)IBA
02/2019 - 12/2005
4Simvastatin (Zocor)FDA LinkGeneric
01/2013 - 12/2005
4Atorvastatin (Lipitor)FDA Link
03/2008 - 07/2003
3Rosuvastatin Calcium (Crestor)FDA Link
12/2008 - 08/2007
2Apolipoprotein E2IBA
09/2021 - 06/2019
2mipomersenIBA
11/2019 - 03/2010
2HDL CholesterolIBA
04/2017 - 12/2008
2Heparan Sulfate Proteoglycans (Heparan Sulfate Proteoglycan)IBA
04/2017 - 01/2017
2alirocumabIBA
12/2015 - 12/2014
2Monoclonal AntibodiesIBA
12/2015 - 01/2015
2Hydroxymethylglutaryl CoA Reductases (HMG CoA Reductase)IBA
03/2014 - 01/2013
2Proteins (Proteins, Gene)FDA Link
08/2007 - 03/2007
1Lipoprotein(a)IBA
06/2019
1Lipoprotein Lipase (Diacylglycerol Lipase)IBA
04/2019
1Apolipoprotein A-VIBA
04/2019
1Apolipoprotein E4IBA
02/2019
1Protein Isoforms (Isoforms)IBA
02/2019
1Rosiglitazone (Avandia)FDA Link
01/2018
12,4-thiazolidinedione (thiazolidinedione)IBA
01/2018
1BezafibrateIBA
11/2017
1Fibric Acids (Fibrates)IBA
04/2017
1SulfatasesIBA
01/2017
1GlucocorticoidsIBA
08/2014
1Therapeutic UsesIBA
08/2014
1AerosolsIBA
03/2014
1BMS201038IBA
01/2013
1Interleukin-12 Subunit p40IBA
01/2013
1Colesevelam Hydrochloride (Welchol)FDA Link
02/2010
1Pravastatin (Pravachol)FDA LinkGeneric
12/2008
1C-Reactive ProteinIBA
04/2008
1Ezetimibe (Zetia)FDA Link
04/2008
1Lipoprotein-XIBA
04/2006
1SodiumIBA
04/2006
1SterolsIBA
02/2004
1avasimibeIBA
12/2003
1Acyl Coenzyme A (Acyl CoA)IBA
12/2003
1Sterol O-AcyltransferaseIBA
12/2003
1polyacrylamideIBA
01/2003
1GelsIBA
01/2003
1Apolipoproteins B (ApoB)IBA
01/2003
1Sepharose (Agarose)IBA
01/2003

Therapy/Procedure

10Therapeutics
09/2021 - 12/2005
1Immunomodulation
01/2013
1Surgical Portacaval Shunt (Portacaval Anastomosis)
03/2008
1Plasmapheresis
03/2008
1Blood Component Removal (Apheresis)
12/2005